Acquisition / mergerFiled on BSE ·
Lloyds Metals and Energy credits 3.5 crore shares of Thriveni Earthmovers
Lloyds Metals · Minerals & Mining
What the filing says
- Shares credited on 08 October 2026 to Lloyds Metals and Energy's demat account
- Allotment of 3,50,00,000 equity shares of Thriveni Earthmovers and Infra Pvt Ltd
- Total consideration for shares ₹606.76 crore, as per allotment on 28 September 2026
Original filing
Update On Acquisition Of Equity Stake In Thriveni Earthmovers And Infra Private Limited.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Lloyds Metals
- Capex / expansionLloyds Metals & Energy reports record H1FY27 production across key segments
- Acquisition / mergerLloyds Metals acquires additional 3.5 crore shares in Thriveni Earthmovers
- Fundraise / allotmentLloyds Metals and Energy approves ESOP shares allotment, capacity expansion, and NCD issuance
- Fundraise / allotmentLloyds Metals approves equity allotment, NCD issue, and DRI plant capacity increase
Other acquisition / merger filings this fortnight
- Acquisition / mergerMeghmani Organi.Meghmani Organics Limited announces NCLT sanction of merger with subsidiaries
- Acquisition / mergerShakti PumpsShakti Pumps invests ₹10 crore in wholly owned subsidiary Shakti Energy Solutions
- Acquisition / mergerElevate Campuses LtdElevate Campuses Limited subscribes to Class A OCRPS in Elevate UAE for ₹601 crore
- Acquisition / mergerTata Consultancy Services LtdTata Consultancy Services Ltd reports Q2 and H1 FY 2026-27 results, declares interim dividend
- Acquisition / mergerTata Consultancy Services LtdTata Consultancy Services reports Q2 & H1 FY 2026-27 results, declares interim dividend
- Acquisition / mergerSudarshan Pharma Industries LtdSudarshan Pharma terminates acquisition of 9.50% equity in Med Therapy Biotechnology Inc.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.